MedTrace Logo

VItamin K Inhibition and NeurocoGnition (VIKING)

NCT03276377 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-09-13

No results posted yet for this study

Summary

The primary objective of this study is to determine whether patients usually taking Vitamin K Antagonists (VKAs) exhibit a poorer global cognitive performance than control patients (matched on age, gender and indication for anticoagulation) taking direct oral anticoagulants (DOACs).

The secondary objectives are:

* to determine whether patients usually taking VKAs are more likely to have moderate to severe cognitive disorders than matched controls taking DOACs.
* to determine whether VKAs intake is associated with poorer executive functions.
* to determine on CT scans whether the VKAs intake is associated with a greater volume of vascular calcifications in the brain compared to the use of DOACs.

Conditions

  • Neurocognitive Disorders

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-30
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276377 on ClinicalTrials.gov